camrelizumab

Org: Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,

Abstract

Modulation of lipid metabolism associated with response to metronomic capecitabine plus camrelizumab in patients with refractory gastrointestinal cancer: A prospective, single-center, exploratory trial.

Org: Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China, Department of Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China,

Abstract

Updated results on multiple antigens stimulating cellular therapy (MASCT-I) in metastatic urothelial carcinoma: A randomized, open-label, phase I trial.

Org: HRYZ Biotech Co. Ltd.,

Abstract

Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.

Org: 900 Hospital of the Joint Logistics Support Force, The First Affiliated Hospital of Anhui Medical University,

Abstract

Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.

Org: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany, Chinese University of Hong Kong, Hong Kong, China, Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China, Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China, Department of Interventional Radiology, Hunan Cancer Hospital, Changsha, China, Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, China, Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China, Department of General Surgery, Anhui Provincial Hospital, Hefei, China, Department of Medical Oncology, Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, China, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Liver Cancer Center, Guangzhou, China, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, State Autonomous Budgetary Healthcare Institution, Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan, Ufa, Russian Federation, Department of Infectious Disease and Hepatology, Wroclaw Medical University, and Centrum Badań Klinicznych P.Napora, Wroclaw, Poland, Department of Liver and Pancreas Gland Oncosurgery, Communal Non-profit Enterprise "Regional Center of Oncology", Kharkiv, Ukraine, Jiangsu Hengrui Pharmaceuticals, Co., Ltd, Shanghai, China, National Taiwan University Hospital, Taipei, Taiwan, Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, Cancer Center of Nanjing, Jinling Hospital, Nanjing, China,

Abstract

Impact of time-of-day infusion of camrelizumab combined with chemotherapy on efficacy in advanced malignant tumors.

Org: Department of General Practice, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China, Guangdong Second Provincial General Hospital, Guangzhou, China, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China, Beijing Friendship Hospital, Beijing, China,

Abstract

Apatinib and camrelizumab plus Intravenous FOLFOX or hepatic arterial infusion chemotherapy with FOLFOX for advanced HCC: A multicenter, prospective, randomized phase III trial.

Org: Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan, China, Sun Yat-sen Memorial Hospital, Sun Yat-sen University Cancer Center Gansu Hospital, Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,

Abstract

Phase II trial of intravesical camrelizumab in BCG-unresponsive high-risk non-muscle invasive bladder cancer.

Org: Tong Ji University,

Abstract

Camrelizumab plus apatinib for advanced renal cell carcinoma patients after first-line tyrosine kinase inhibitor treatment failure: A multicenter phase II trial.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Medical Imaging, Nuclear Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Department of General Internal Medicine,

Abstract

Camrelizumab plus apatinib and temozolomide as first-line therapy for advanced acral melanoma: 2-year survival results from CAP 03.

Org: Department of Melanoma and Sarcoma Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Melanoma Institute Australia, Department of Genitourinary Oncology,

Abstract

Neoadjuvant immunochemotherapy and new radiomic predictor for resectable locally advanced oral squamous cell carcinoma.

Org: Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China, State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Department of Head and Neck Oncology Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, China, State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases and Department of Oral Pathology, West China Hospital of Stomatology, Sichuan University, Chengdu, China, State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases and Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, China,

Abstract

Updated results from venous infusion chemotherapy (VIC) plus apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.

Org: Department of Hepatobiliary Surgery,

Abstract

Apatinib and camrelizumab plus hepatic arterial infusion with oxaliplatin and 5-fluorouracil vs. apatinib and camrelizumab as the first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A randomized multi-center clinical trial.

Org: Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China,

Abstract

The clinical application of circulating tumor cells (CTCs) for immunotherapy in advanced pancreatic cancer.

Org: Cancer Research Center, Beijing Chest Hospital, Capital Medical University/ Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijin, China, Department of Oncology, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China, Department of of Pathology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Cytelligen, San Diego, CA,

Abstract

Neoadjuvant chemo-immunotherapy following concurrent immuno-chemoradiotherapy and immune-maintenance therapy as primary treatment for locally advanced cervical cancer: A prospective, single-arm, phase 2 trial.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,

Abstract

Open-label, prospective phase 2 study to evaluate the efficacy and safety of camrelizumab combined with etoposide and cisplatin as neoadjuvant therapy in patients with neuroendocrine carcinoma of the cervix.

Org: Clinical Oncology School of Fujian Medical University,

Abstract

A propensity-matched cohort study of neoadjuvant immunotherapy combined with chemotherapy versus neoadjuvant chemotherapy for early-stage triple-negative breast cancer.

Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,

Abstract

Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis.

Org: Niterói, Acre Federal University, Federal University of Santa Catarina, Florianopolis, Viçosa Federal University,

Abstract

Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study.

Org: Department of Gastroenterological Surgery II, Hokkaido University, Faculty of Medicine, Sapporo, Japan, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China,

Abstract

Preliminary data of a phase Ib/II trial evaluating the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular carcinoma.

Org: Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China,

Abstract

Hepatic artery infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced hepatocellular carcinoma with portal vein tumor thrombus: A single center retrospective study.

Org: Department II of Interventional Radiology,

Abstract

Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC): A single-center, single-arm, exploratory clinical trial.

Org: The Affifiliated Hospital of Qingdao University,

Abstract

Hepatic artery infusion of FOLFOX chemotherapy and camrelizumab combined with sorafenib for advanced stage hepatocellular carcinoma (Double-IA-001): A phase II trial.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,

Abstract

Associations of ctDNA clearance and pathological response after neoadjuvant treatment in patients with locally advanced oral cancer.

Org: Oromaxillofacial Head and Neck Surgery, Huashan Hospital, Fudan University,

Abstract

Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial.

Org: Department of Biotherapy, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University, Chengdu Origen Biotechnology,

Abstract

Safety and efficacy of camrelizumab and apatinib in combination with IMRT in unresectable hepatocellular carcinoma: A non-randomised phase 2 study.

Org: Department of Hepatopancreatobiliary Surgery Unit I,

Abstract

Role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) in unresectable hepatocellular carcinoma (uHCC): Subgroup analysis of patients treated with camrelizumab (cam) + rivoceranib (rivo) in the CARES-310 trial.

Org: Hong Kong Cancer Institute,

Abstract

A randomized controlled study on perioperative treatment of esophageal squamous cell carcinoma with camrelizumab combined with nab-paclitaxel and cisplatin.

Org: Zhengzhou University First Affiliated Hospital, Jiangsu Hengrui Pharmaceuticals Co.,Ltd,

Abstract

A single-arm exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma.

Org: Jiangsu Simcere Diagnostics Co., Ltd., Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Graduate School of Dalian Medical University,

Abstract

A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma.

Org: Department of Medical Oncology, The First Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, Anyang Tumor Hospital, Anyang, Henan, China, Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China, Nanyang Medical College First Affiliated Hospital, Nanyang, China, Department of Oncology, Anyang Tumor Hospital, Anyang, Henan, China, Xinyang Tumor Hospital, Xinyang, China,

Abstract

Camrelizumab combined with apatinib as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A phase 2 trial.

Org: The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, First Affiliated Hospital of Zhengzhou University,

Abstract

Preliminary results of a randomized controlled, open-label, multi-center phase II study of camrelizumab combined with chemotherapy followed by concurrent chemoradiotherapy and camrelizumab consolidation therapy versus standard chemoradiotherapy as first-line treatment for limited-disease small cell lung cancer.

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shanghai Pulmonary Hospital, Shanghai, China, Tongji University School of Medicine, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Department of Pulmonary and Critical Care Medicine,

Abstract

Molecular imaging research on 18F-FDG PET/CT and biomarker analysis to predict the efficacy of neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIB NSCLC.

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Shandong Cancer Hospital Affiliated to Shandong University,

Abstract

Efficacy and safety of transarterial therapy combined with donafenib plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A multicenter retrospective study.

Org: Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China, Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Department of Minimally Invasive Interventional Radiology, Hexian Hospital of Panyu District, Guangzhou, China, Department of Hepatobiliary Surgery, The First People’s Hospital of Foshan, Guangdong, China, Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China,

Abstract

Comparative efficacy of six programmed cell death protein-1 inhibitors in first-line treatment for advanced non-small cell lung cancer: A retrospective cohort study.

Org: Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital,

Abstract

Predictive value of baseline 68Ga‑FAPI PET/CT in the first-line therapy of pancreatic ductal adenocarcinoma (PDAC).

Org: Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Chinese Academy of Medical Sciences and Peking Union Medical College,

Abstract

An open-label, placebo-controlled, randomized phase II trial of camrelizumab combined with or without apatinib or capecitabine in the treatment of previously treated advanced pancreatic cancer.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Fudan University Shanghai Cancer Center, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine,

Abstract

Camrelizumab combined with chemotherapy followed by maintenance camrelizumab and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory study.

Org: Harbin Medical University Cancer Hospital, Harbin, China,

Abstract

Updated efficacy and safety results from the phase Ib/II study of surufatinib combined with camrelizumab and chemotherapy in patients with advanced colorectal cancer.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Jiangsu Cancer Hospital, Nanjing, China,

Abstract

Preliminary efficacy and safety of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial.

Org: Department of Head & Neck Tumors and Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center; Shanghai Medical College, Fudan University, Shanghai, China, Minimally Invasive Therapy Center, Shanghai Cancer Center, Fudan University, Shanghai, China, Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,

Abstract

Efficacy and safety analysis of donafenib combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: A prospective, single-arm, single center, phase II clinical study.

Org: Intervention Ward One,

Abstract

Neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIb non-small cell lung cancer: Single arm phase II study.

Org: Shandong Academy of Medical Sciences,

Clinical trial

Single-arm, Prospective Clinical Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma With High Tumor Load

Status: Recruiting, Estimated PCD: 2026-04-11

Clinical trial

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma: a Multicenter, Prospective, Randomized Controlled Trial

Status: Recruiting, Estimated PCD: 2026-08-15

Clinical trial

Apatinib in Combination With Ifosfamide and Etoposide (IE) for Relapsed or Refractory Osteosarcoma Progressed Upon First-line Chemotherapy (AIEO): a Prospective, Multiple-centre, Single-arm, Phase 2 Trial

Status: , Estimated PCD: 2026-04-01

Clinical trial

Efficacy and Safety of Conversion Therapy With Sintilimab in Combination With Chemotherapy and Apatinib in Patients With Stage IV Gastric Cancer

Status: Active (not recruiting), Estimated PCD: 2022-12-01

Abstract

Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial.

Org: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Department of Radiology, Fudan University Shanghai Cancer Center, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital,

Abstract

FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.

Org: Fudan University Shanghai Cancer Center, Jiangsu Hengrui Pharmaceuticals Co., Ltd.,

Abstract

Camrelizumab in combination with apatinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: A prospective, single-arm, phase 2 study.

Org: Tianjin Medical University Cancer Hospital & Institute, Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan, China, Liver Cancer Research Center for Prevention and Therapy, Tianjin Cancer Hospital Airport Hospital, Liver Cancer Center,

Abstract

Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study.

Org: The First Affiliated Hospital of Fujian Medical University, Fujian Provincial Hospital, Zhangzhou Hospital Affiliated to Fujian Medical University, Xiamen Hospital of Traditional Chinese Medicine, Mengchao Hepatobiliary Hospital of Fujian Medical University,

Abstract

Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial.

Org: Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Breast Medicine Service, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China,

Abstract

The overall survival analysis of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer—An open-label, single-arm, phase 2 trial.

Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Fudan University (Xiamen Branch), Shanghai Cancer Center, Shanghai, China, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,

Abstract

Efficacy and safety of camrelizumab in combination with radiation and chemotherapy for recurrent or metastatic cervical cancer.

Org: Tianjin Medical University Cancer Hospital & Institute, Tianjin Medical university cancer institute & Hospital, Tianjin Cancer Hospital Airport Hospital,

Abstract

A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage.

Org: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Qilu Hospital of Shandong University,

Abstract

A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.

Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China,

Abstract

A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck.

Org: Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Department of Otolaryngology Head and Neck Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University,

Abstract

Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial.

Org: Tianjin Medical University Cancer Hospital & Institute, Tianjin Medical university cancer institute & Hospital, National Clinical Research Center for Cancer,

Abstract

Neoadjuvant short-course radiotherapy followed by chemotherapy plus camrelizumab versus long-course chemoradiotherapy followed by chemotherapy for patients with locally advanced rectal cancer: A randomized, multicenter, open-label phase 3 trial (Union).

Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, Hubei, China,

Abstract

Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.

Org: Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China, Women's Hospital School of Medicine Zhejiang University,

Abstract

Cerebrospinal fluid immunological cytokines to predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases: GASTO 1060.

Org: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangdong, Guangdong, China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China,

Abstract

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.

Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China National Biotec Group, Shandong Suncadia Medicine,

Abstract

A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).

Org: Senior Department of Oncology, the 5th Medical Center of the PLA General Hospital, Beijing, China, Medical Affairs Department, 3D Medicines, Shanghai, China,

Abstract

Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospective, randomized controlled study.

Org: The First Affiliated Hospital of Anhui Medical University, Hefei, China National Biotec Group, Fuyang Cancer Hospital, Anqing Municipal Hospital,

Abstract

Camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma: A single-arm, multicenter, exploratory study.

Org: Cancer Centre of Southeastern Ontario/Queen's University, The First Hospital of Jilin University, Changchun, Jilin Province, China, Changchun, China,

Abstract

Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).

Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Beijing InnoCare Pharma Tech, China National Biotec Group, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi City,

Abstract

Neoadjuvant immunotherapy in hepatocellular carcinoma: A systematic review and meta-analysis.

Org: Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT, UMass Chan Medical School, Shrewsbury, MA,

Abstract

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate as neoadjuvant therapy for osteosarcoma: A single-arm, exploratory phase II trial.

Org: Sun Yat-sen University Cancer Center Gansu Hospital,

Abstract

Donafenib combined with camrelizumab and transarterial chemoembolization (TACE) as conversion therapy for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm, phase II study.

Org: Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China, Nanjing, China, Department of Radiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China, Nanjing, Jiangsu, China, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China, Nanjing, Jiangsu, China, Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China, Nanjing, Jiangsu, China, Department of Radiology, Nanjing Drum Tower Hospital, Th...,

Abstract

Preliminary efficacy and safety of camrelizumab plus metronomic oral vinorelbine as first-line therapy for people aged 70 and above with advanced non-small cell lung cancer (NSCLC) from a phase II trial.

Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Beijing Hospital of Traditional Chinese Medicine,

Abstract

Clinical efficacy and safety of immune checkpoint inhibitor in combination with regorafenib therapy as second⁃line regimen for patients with unresectable hepatocellular carcinoma.

Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Shandong Cancer Hospital and Institute, Jinan, shandong, China, Shandong Cancer Hospital and Institute, Jinan, China,

Abstract

Long-term survival outcomes and immune checkpoint inhibitor (ICI) retreatment in patients with advanced cervical cancer who received camrelizumab plus apatinib in the CLAP study.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, The First Affiliated Hospital of Sun Yat-sen University, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Clinical Oncology School of Fujian Medical University,

Abstract

Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.

Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China, Department of Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China,

Abstract

Phase II trial of camrelizumab plus apatinib in combination with stereotactic body radiotherapy (SBRT) in patients with recurrent/metastatic non–clear-cell renal cell carcinoma (nccRCC).

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, Guangdong, China,

Abstract

Venous infusion chemotherapy (VIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.

Org: Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Department of Radiology, Sun Yat-sen Memorial hospital of Sun Yat-sen university, Guangzhou, China,

Abstract

Transarterial chemoembolization combined with camrelizumab and apatinib in the treatment of advanced hepatocellular carcinoma: Preoperative or postoperative combination? A prospective clinical study.

Org: Fifth Medical Center of Chinese PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group, Aerospace Medical Center, Aerospace Center Hospital,

Abstract

Value of Patlak-Ki from ultra-high sensitivity dynamic total body [18F]FDG PET/CT for evaluation of treatment response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer (LA-NSCLC) patients.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, United-Imaging Healthcare, Molecular Imaging Business Unit,

Abstract

Association of neutrophil/lymphocyte ratio and IFN-γ with clinical response and survival in patients with MSS/pMMR mCRC treated with anti-PD-1 and VEGF inhibitors.

Org: Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai Tenth People's Hospital Chongming Branch, Department of Oncology, Shanghai Tenth People's Hospital,

Abstract

A single-center, prospective, single-arm, phase II trial to evaluate the adjuvant efficacy of camrelizumab with docetaxel plus S-1 for stage III (PD-L1+/dMMR/EBV+) gastric cancer after D2 resection.

Org: Shanghai Jiaotong University School of Medicine, Renji Hospital Shanghai Jiaotong University School of Medicine,

Abstract

Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).

Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, The central hospital of lishui city, Lishui, China, Department of Gastroenterology,Harbin Medical University Cancer Hospital, Harbin, China, Hunan Provincial People's Hospital, Changsha, China,

Abstract

Camrelizumab combined with tyrosine kinase inhibitors in the treatment of patients with advanced renal cell carcinoma: A single-center prospective exploratory study.

Org: Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Huaiyin District Jinan, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China,

Abstract

Hepatic artery infusion chemotherapy combined with donafenib and camrelizumab in patients with unresectable hepatocellular carcinoma presenting portal vein tumor thrombus: A prospective, single-arm study.

Org: Chongqing Medical University,

Abstract

Efficacy and safety of camrelizumab and apatinib combined with neoadjuvant concurrent chemoradiation for MSS locally advanced rectal cancer.

Org: Affiliated Hospital of Qingdao University, Qingdao University Affiliated Hospital,

Abstract

Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): A single-arm, open-label, phase 2 trial.

Org: Department of Thoracic Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 1st Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, MD Anderson Cancer Center, Houston, TX, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Department of Radiation Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China,

Abstract

Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): A single-arm, phase Ⅱ trial.

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Gastrointestinal Surgery Center, Department of Gastroenterology and Urology, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,

Abstract

Efficacy and safety of camrelizumab combined with apatinib in the treatment of advanced gastric cancer: Preliminary results from a multicenter, prospective study.

Org: The First Affiliated Hospital of University of Science and Technology of China, Chaohu Hospital of Anhui Medical University, People's Liberation Army Navy Anqing Hospital, The Second Hospital of Anhui Medical University, Hefei, China, Anhui No.2 Provincial People's Hospital,

Abstract

Neoadjuvant camrelizumab plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A single-arm, phase II trial.

Org: The First Affiliated Hospital of University of Science and Technology of China, Hefei, China, Anhui Provincial Cancer Hospital, Hefei, China, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China,

Abstract

Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: A retrospective analysis.

Org: Harbin Medical University Cancer Hospital, Harbin, China,

Abstract

Multiple antigen stimulating cellular therapy (MASCT)-I for metastatic urothelial carcinoma (mUC): A multicenter, phase I study (MASCT-I-1001).

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China,

Abstract

Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study).

Org: Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital Southern Medical University, Guangzhou, China, Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China,

Product

Camrelizumab plus Famitinib